Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets
- PMID: 7506454
- DOI: 10.1097/00007890-199312000-00039
Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets
Abstract
Pancreatic islet transplantation may be the most ideal treatment for patients with insulin-dependent diabetes mellitus. However, immunosuppressive agents such as cyclosporine A(CsA) and FK506, used for these transplanted patients have been reported to cause glucose intolerance. In the present study, we have compared the effects of CsA and FK506 on glucose-stimulated insulin release from the isolated dog pancreatic islets, which have been maintained in culture for 3 days after isolation. The isolated dog pancreatic islets, pretreated for 24 hr with either CsA or FK506 (1, 10, and 100 nM), were perifused with 16.7 mM glucose. Pretreatment with both drugs suppressed glucose-stimulated insulin secretion in a dose-dependent fashion. CsA (100 nM), which is a therapeutically relevant concentration, significantly suppressed both the first and second phases of glucose-stimulated insulin release compared with 100 nM FK506. These findings suggest that, with a therapeutically relevant concentration, FK506 may be less toxic than CsA against pancreatic islets in patients with organ or cell transplantation.
Similar articles
-
Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506.Transplantation. 1993 Jan;55(1):186-92. doi: 10.1097/00007890-199301000-00035. Transplantation. 1993. PMID: 7678356
-
Functional and morphological study of cultured pancreatic islets treated with cyclosporine.Life Sci. 2007 Jan 2;80(4):345-55. doi: 10.1016/j.lfs.2006.09.034. Epub 2006 Oct 5. Life Sci. 2007. PMID: 17074365
-
Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells.Acta Diabetol. 2002 Dec;39(4):229-33. doi: 10.1007/s005920200039. Acta Diabetol. 2002. PMID: 12486498
-
[Glucose intolerance induced by tacrolimus (FK506), cyclosporin A].Nihon Rinsho. 2005 Feb;63 Suppl 2:333-7. Nihon Rinsho. 2005. PMID: 15779398 Review. Japanese. No abstract available.
-
Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation.J Transl Med. 2007 Jan 3;5:1. doi: 10.1186/1479-5876-5-1. J Transl Med. 2007. PMID: 17201925 Free PMC article. Review.
Cited by
-
Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.Drugs. 1997 Dec;54(6):925-75. doi: 10.2165/00003495-199754060-00009. Drugs. 1997. PMID: 9421697 Review.
-
CMV prophylaxis: a useful step towards prevention of post-transplant diabetes?Diabetologia. 2004 Sep;47(9):1473-5. doi: 10.1007/s00125-004-1500-x. Epub 2004 Aug 25. Diabetologia. 2004. PMID: 15338130 Review. No abstract available.
-
Oral administration of ginseng ameliorates cyclosporine-induced pancreatic injury in an experimental mouse model.PLoS One. 2013 Aug 29;8(8):e72685. doi: 10.1371/journal.pone.0072685. eCollection 2013. PLoS One. 2013. PMID: 24009697 Free PMC article.
-
Post-transplant diabetes mellitus. The role of immunosuppression.Drug Saf. 1997 Apr;16(4):242-57. doi: 10.2165/00002018-199716040-00002. Drug Saf. 1997. PMID: 9113492 Review.
-
Pregnancy Outcomes Following Pediatric Liver Transplantation: A Single-Center Experience in Japan.Ann Transplant. 2020 Jun 9;25:e921193. doi: 10.12659/AOT.921193. Ann Transplant. 2020. PMID: 32513910 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical